OFEV (nintedanib)

OFEV (nintedanib) 

SELF ADMINISTRATION - ORAL

Indications for Prior Authorization:

• Treatment of idiopathic pulmonary fibrosis (IPF)

Patients must meet the following criteria for the indication(s) above:

• Diagnosis if IPF by pulmonologist

The Following Conditions Do Not Meet the Criteria for Use as Established by the WHA P & T Committee:

• All non-FDA approved uses not listed in the approved indications

Dosing:

• The recommended dose is 150 mg twice a day with food
• Should be given 12 hours apart
• Dose modification is required for adverse events and elevated liver function tests

Approval:

One year